Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.
Target Price
The average target price of IKT is 6.5 and suggests 292% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell